TWI707678B - 以週劑量療程用於哺乳動物之抗發炎及源自退化性關節疾病疼痛之吡唑啉衍生化合物及其用途 - Google Patents
以週劑量療程用於哺乳動物之抗發炎及源自退化性關節疾病疼痛之吡唑啉衍生化合物及其用途 Download PDFInfo
- Publication number
- TWI707678B TWI707678B TW104134072A TW104134072A TWI707678B TW I707678 B TWI707678 B TW I707678B TW 104134072 A TW104134072 A TW 104134072A TW 104134072 A TW104134072 A TW 104134072A TW I707678 B TWI707678 B TW I707678B
- Authority
- TW
- Taiwan
- Prior art keywords
- treatment
- dose
- body weight
- administered
- day
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 72
- 208000002193 Pain Diseases 0.000 title claims abstract description 64
- 230000003442 weekly effect Effects 0.000 title claims abstract description 57
- 230000036407 pain Effects 0.000 title claims abstract description 55
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 39
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 37
- 241000124008 Mammalia Species 0.000 title abstract description 15
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 title 1
- ZZMJXWXXMAAPLI-UHFFFAOYSA-N 4-[3-(2,4-difluorophenyl)-5-(trifluoromethyl)-3,4-dihydropyrazol-2-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C(=CC(F)=CC=2)F)CC(C(F)(F)F)=N1 ZZMJXWXXMAAPLI-UHFFFAOYSA-N 0.000 claims abstract description 160
- 238000011282 treatment Methods 0.000 claims abstract description 153
- 241000282472 Canis lupus familiaris Species 0.000 claims abstract description 59
- 230000037396 body weight Effects 0.000 claims description 96
- 238000012423 maintenance Methods 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 32
- 206010022562 Intermittent claudication Diseases 0.000 claims description 29
- 208000024980 claudication Diseases 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 13
- 208000000094 Chronic Pain Diseases 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000030175 lameness Diseases 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 25
- 206010003246 arthritis Diseases 0.000 description 23
- 230000006698 induction Effects 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 239000000725 suspension Substances 0.000 description 9
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 8
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 8
- 230000001760 anti-analgesic effect Effects 0.000 description 8
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 230000003412 degenerative effect Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 5
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 5
- 229940111134 coxibs Drugs 0.000 description 5
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000011287 therapeutic dose Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 241000282465 Canis Species 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 208000026816 acute arthritis Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000004195 Isomerases Human genes 0.000 description 3
- 108090000769 Isomerases Proteins 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KYXDNECMRLFQMZ-UHFFFAOYSA-N cimicoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=C(Cl)N=CN1C1=CC=C(S(N)(=O)=O)C=C1 KYXDNECMRLFQMZ-UHFFFAOYSA-N 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000011866 long-term treatment Methods 0.000 description 3
- TTZNQDOUNXBMJV-UHFFFAOYSA-N mavacoxib Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 TTZNQDOUNXBMJV-UHFFFAOYSA-N 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 238000002559 palpation Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- -1 pyrazoline derivative compound Chemical class 0.000 description 3
- ZEXGDYFACFXQPF-UHFFFAOYSA-N robenacoxib Chemical compound OC(=O)CC1=CC(CC)=CC=C1NC1=C(F)C(F)=CC(F)=C1F ZEXGDYFACFXQPF-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000012659 Joint disease Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940043081 onsior Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940106299 previcox Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000005065 subchondral bone plate Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950010851 cimicoxib Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011833 dog model Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002524 firocoxib Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000001981 hip bone Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229950007241 mavacoxib Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000205 robenacoxib Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382396.1A EP3009137A1 (en) | 2014-10-16 | 2014-10-16 | Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals |
| EP14382396.1 | 2014-10-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201625239A TW201625239A (zh) | 2016-07-16 |
| TWI707678B true TWI707678B (zh) | 2020-10-21 |
Family
ID=51844648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104134072A TWI707678B (zh) | 2014-10-16 | 2015-10-16 | 以週劑量療程用於哺乳動物之抗發炎及源自退化性關節疾病疼痛之吡唑啉衍生化合物及其用途 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11154536B2 (enExample) |
| EP (2) | EP3009137A1 (enExample) |
| JP (1) | JP6655625B2 (enExample) |
| CN (2) | CN115154465A (enExample) |
| AR (1) | AR102295A1 (enExample) |
| CA (1) | CA2964428C (enExample) |
| CY (1) | CY1123243T1 (enExample) |
| DK (1) | DK3206684T3 (enExample) |
| ES (1) | ES2828435T3 (enExample) |
| HR (1) | HRP20201233T1 (enExample) |
| HU (1) | HUE050511T2 (enExample) |
| LT (1) | LT3206684T (enExample) |
| MX (1) | MX376725B (enExample) |
| PL (1) | PL3206684T3 (enExample) |
| PT (1) | PT3206684T (enExample) |
| RS (1) | RS60777B1 (enExample) |
| SI (1) | SI3206684T1 (enExample) |
| SM (1) | SMT202000415T1 (enExample) |
| TW (1) | TWI707678B (enExample) |
| WO (1) | WO2016059028A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109303784B (zh) * | 2018-09-30 | 2020-06-23 | 山东省文登整骨医院 | 痛风性关节炎动物模型的构建方法 |
| TWI875757B (zh) * | 2019-05-08 | 2025-03-11 | 瑞士商諾華公司 | T1dm和胰島炎治療中使用之抗cd40抗體 |
| EP4029502A1 (en) | 2021-01-15 | 2022-07-20 | Ecuphar N.V. | Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals |
| US12208085B2 (en) | 2022-05-31 | 2025-01-28 | Ecuphar Nv | Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1083171B1 (en) * | 1998-05-29 | 2004-04-28 | Laboratorios Del Dr. Esteve, S.A. | Pyrazoline derivatives, their preparation and application as medicaments |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU773615B2 (en) * | 1997-05-05 | 2004-05-27 | Pfizer Inc. | COX-2 selective carprofen for treating pain and inflammation in dogs |
| US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
| CN101175769A (zh) * | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | 用于调控血管完整性的方法和组合物 |
-
2014
- 2014-10-16 EP EP14382396.1A patent/EP3009137A1/en not_active Withdrawn
-
2015
- 2015-10-13 ES ES15778958T patent/ES2828435T3/es active Active
- 2015-10-13 CN CN202210698831.5A patent/CN115154465A/zh active Pending
- 2015-10-13 SM SM20200415T patent/SMT202000415T1/it unknown
- 2015-10-13 DK DK15778958.7T patent/DK3206684T3/da active
- 2015-10-13 CN CN201580068592.3A patent/CN107257684A/zh active Pending
- 2015-10-13 PT PT157789587T patent/PT3206684T/pt unknown
- 2015-10-13 RS RS20200943A patent/RS60777B1/sr unknown
- 2015-10-13 MX MX2017004899A patent/MX376725B/es active IP Right Grant
- 2015-10-13 US US15/518,871 patent/US11154536B2/en active Active
- 2015-10-13 PL PL15778958T patent/PL3206684T3/pl unknown
- 2015-10-13 SI SI201531302T patent/SI3206684T1/sl unknown
- 2015-10-13 HR HRP20201233TT patent/HRP20201233T1/hr unknown
- 2015-10-13 WO PCT/EP2015/073635 patent/WO2016059028A1/en not_active Ceased
- 2015-10-13 EP EP15778958.7A patent/EP3206684B1/en active Active
- 2015-10-13 CA CA2964428A patent/CA2964428C/en active Active
- 2015-10-13 HU HUE15778958A patent/HUE050511T2/hu unknown
- 2015-10-13 LT LTEP15778958.7T patent/LT3206684T/lt unknown
- 2015-10-13 JP JP2017539508A patent/JP6655625B2/ja active Active
- 2015-10-16 AR ARP150103353A patent/AR102295A1/es not_active Application Discontinuation
- 2015-10-16 TW TW104134072A patent/TWI707678B/zh active
-
2020
- 2020-08-03 CY CY20201100714T patent/CY1123243T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1083171B1 (en) * | 1998-05-29 | 2004-04-28 | Laboratorios Del Dr. Esteve, S.A. | Pyrazoline derivatives, their preparation and application as medicaments |
Non-Patent Citations (1)
| Title |
|---|
| Biopharm. Drug Dispos. 22: 231–242 (2001) * |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3206684T3 (da) | 2020-08-10 |
| HRP20201233T1 (hr) | 2020-11-13 |
| CN115154465A (zh) | 2022-10-11 |
| MX376725B (es) | 2025-03-07 |
| PL3206684T3 (pl) | 2021-01-11 |
| WO2016059028A1 (en) | 2016-04-21 |
| EP3206684A1 (en) | 2017-08-23 |
| AR102295A1 (es) | 2017-02-15 |
| HUE050511T2 (hu) | 2020-12-28 |
| ES2828435T3 (es) | 2021-05-26 |
| CY1123243T1 (el) | 2021-10-29 |
| JP6655625B2 (ja) | 2020-02-26 |
| CN107257684A (zh) | 2017-10-17 |
| PT3206684T (pt) | 2020-08-24 |
| EP3009137A1 (en) | 2016-04-20 |
| TW201625239A (zh) | 2016-07-16 |
| CA2964428A1 (en) | 2016-04-21 |
| JP2017531042A (ja) | 2017-10-19 |
| LT3206684T (lt) | 2020-10-12 |
| CA2964428C (en) | 2022-01-04 |
| SI3206684T1 (sl) | 2020-11-30 |
| US20170231961A1 (en) | 2017-08-17 |
| US11154536B2 (en) | 2021-10-26 |
| EP3206684B1 (en) | 2020-06-17 |
| RS60777B1 (sr) | 2020-10-30 |
| MX2017004899A (es) | 2018-02-12 |
| SMT202000415T1 (it) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201615221A (zh) | 炎症用藥臨床新應用 | |
| AU2006232644B2 (en) | Anti-inflammatory formulation | |
| JP2007302657A (ja) | 痙症の兆候および症候の緩和方法 | |
| TWI707678B (zh) | 以週劑量療程用於哺乳動物之抗發炎及源自退化性關節疾病疼痛之吡唑啉衍生化合物及其用途 | |
| Hu et al. | Evaluation of the analgesic effects of phenylbutazone administered at a high or low dosage in horses with chronic lameness | |
| Ramzan | The racehorse: A veterinary manual | |
| TW202237107A (zh) | 用於治療疼痛之酚系trpv1促效劑之前藥 | |
| US8642566B2 (en) | Therapeutic approaches for treating neuroinflammatory conditions | |
| Castro-Cuellar | Intra-Articular Buprenorphine in Horses | |
| Langley-Hobbs et al. | Osteoarthritis in cats _ part 2. | |
| McKune | Clinical Management and Pharmacologic Treatment of Pain | |
| JP2018012695A (ja) | ロキソプロフェン又はその塩及びビタミンｂ１２類を含有する経口用医薬組成物 | |
| Pucheu et al. | Multicentric, randomized and positive-controlled study to assess the efficacy of an association of chondroitin sulphate, chitosan, l-selenomethionine and epigallocatechin-3-gallate in the control of osteoarthritis and functional postoperative recovery | |
| AU2020263152A1 (en) | Compositions and methods for potentiating derivatives of 4-Aminophenols | |
| ES2543364A1 (es) | Composición farmacéutica que comprende la combinación de un agente antiinflamatorio no esteroideo, un agente adyuvante y un analgésico antineurítico, con efecto antinociceptivo | |
| Vijarnsorn | Investigation of anti-arthritic effects of a new glucosamine formulation (ONC114). | |
| Vijarnsorn | Investigation of Anti-arthritic Effects of a New Glucosamine Formulation (ONC114). | |
| JP2020506206A (ja) | 治療用組成物 |